180 related articles for article (PubMed ID: 17082235)
1. Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach.
Scarsi M; Podvinec M; Roth A; Hug H; Kersten S; Albrecht H; Schwede T; Meyer UA; Rücker C
Mol Pharmacol; 2007 Feb; 71(2):398-406. PubMed ID: 17082235
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
[TBL] [Abstract][Full Text] [Related]
3. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
Porskjær Christensen L; Bahij El-Houri R
Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
[TBL] [Abstract][Full Text] [Related]
4. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
[TBL] [Abstract][Full Text] [Related]
5. Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones.
Lee KW; Ku YH; Kim M; Ahn BY; Chung SS; Park KS
Diabetes Metab J; 2011 Aug; 35(4):340-7. PubMed ID: 21977453
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Lang VY; Fatehi M; Light PE
Pharmacogenet Genomics; 2012 Mar; 22(3):206-14. PubMed ID: 22209866
[TBL] [Abstract][Full Text] [Related]
7. [Molecular basis of oral hypoglycemic sulfonylurea action].
Owecki M; Horst-Sikorska W; Sowiński J
Pol Merkur Lekarski; 2003 Nov; 15(89):445-8. PubMed ID: 14969140
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of the glycaemic effects of sulfonylureas.
Ashcroft FM
Horm Metab Res; 1996 Sep; 28(9):456-63. PubMed ID: 8911983
[TBL] [Abstract][Full Text] [Related]
9. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity.
Fukuen S; Iwaki M; Yasui A; Makishima M; Matsuda M; Shimomura I
J Biol Chem; 2005 Jun; 280(25):23653-9. PubMed ID: 15764598
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
[TBL] [Abstract][Full Text] [Related]
11. [Structures and mechanisms for non SU insulin secretagogues].
Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
[No Abstract] [Full Text] [Related]
12. Mechanisms and Characteristics of Sulfonylureas and Glinides.
Lv W; Wang X; Xu Q; Lu W
Curr Top Med Chem; 2020; 20(1):37-56. PubMed ID: 31884929
[TBL] [Abstract][Full Text] [Related]
13. Sulfonylurea receptors and mechanism of sulfonylurea action.
Panten U; Schwanstecher M; Schwanstecher C
Exp Clin Endocrinol Diabetes; 1996; 104(1):1-9. PubMed ID: 8750563
[TBL] [Abstract][Full Text] [Related]
14. Application of modified in vitro screening procedure for identifying herbals possessing sulfonylurea-like activity.
Rotshteyn Y; Zito SW
J Ethnopharmacol; 2004 Aug; 93(2-3):337-44. PubMed ID: 15234774
[TBL] [Abstract][Full Text] [Related]
15. Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients.
Susilawati E; Levita J; Susilawati Y; Sumiwi SA
Med Sci (Basel); 2023 Aug; 11(3):. PubMed ID: 37606429
[TBL] [Abstract][Full Text] [Related]
16. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
18. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity.
Nagashima K; Takahashi A; Ikeda H; Hamasaki A; Kuwamura N; Yamada Y; Seino Y
Diabetes Res Clin Pract; 2004 Dec; 66 Suppl 1():S75-8. PubMed ID: 15563985
[TBL] [Abstract][Full Text] [Related]
19. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels.
Chachin M; Yamada M; Fujita A; Matsuoka T; Matsushita K; Kurachi Y
J Pharmacol Exp Ther; 2003 Mar; 304(3):1025-32. PubMed ID: 12604678
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
